Anti-CXCR2 antibodies and uses thereof
AssigneeShanghaitech University
InventorsGuang Yang, Xiaojie Shi, Richard Lerner
Life of this patent
Estimating the term…
Abstract
Provided are anti-CXCR2 antibodies and antigen-binding fragments thereof. The antibodies or fragments thereof specifically bind to N-terminal, extracellular domain of the CXCR2 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, or any one of SQ ID NO: 7-14, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and inflammatory diseases are also provided.
Claims12
An antibody or fragment thereof, wherein the antibody or fragment thereof has specificity to a human C—X—C Motif Chemokine Receptor 2 (CXCR2) protein and comprises a heavy chain variable region (VH) comprising a CDR1, a CDR2 and a CDR3, and a light chain variable region (VL) comprising a CDR1, a CDR2 and a CDR3, wherein:
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO:1;
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO:2;
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO:3, or a variant selected from the group consisting of SEQ ID NO:7-14;
- the VL CDR1 comprises the amino acid sequence of SEQ ID NO:4;
- the VL CDR2 comprises the amino acid sequence of SEQ ID NO:5;
- and
- the VL CDR3 comprises the amino acid sequence of SEQ ID NO:6.
Dependencies are inferred from the claim text.